00:49 , Nov 10, 2017 |  BC Innovations  |  Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...
01:06 , Jul 1, 2016 |  BC Extra  |  Company News

Management tracks

Molecular diagnostics company Epigenomics AG (Xetra:ECX) named Gregory Hamilton CEO. He replaces CEO and CFO Thomas Taapken, who has left the company. Hamilton was CEO at AltheaDx Inc. (San Diego, Calif.). The company expects to...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Financial News

Blueprint Bio completes venture financing

Blueprint Bio Inc. , Newport Beach, Calif.   Business: Diagnostic   Date completed: 2016-06-23   Type: Venture financing   Raised: $7.5 million   Investor: Forentis Fund  ...